SELLAS expects REGAL enrollment ex-China by Nov 2023; China start triggers $13M milestone

SELLAS Life Sciences Group, Inc.

Enrollment outside China expected to complete in November 2023; patient numbers for interim and final analyses already enrolled.
Interim analysis (60 events) on track for late 2023/early 2024; final analysis (80 events) targeted by end of 2024.
China partner 3D Medicines to begin REGAL enrollment in Q4 2023, triggering two milestone payments totaling $13.0 million.
3D Medicines has obtained all regulatory permits and set up 11 treatment centers in China; previously projected Q3 start delayed by supply-chain issues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.